I have the same concerns as others on this forum with Alterity talking about another possible use for ATH434 with FA. My pessimism is that in the event that ATH434 fails to meet the objectives of the phase 2 trials that they will seek to raise new capital to begin a new trial with FA patients. Together with Prana, ATH has been listed on the ASX for over 20 years with no successful commercialization of any of their drugs. If ATH434 fails to progress past a phase 2 trial, I do not see any light in the company going forward. With a share price of less than 1c per share, a failure in the current trial would basically see the share price tank close to no value. ATH434 needs to go past a phase 2 trial. With only 6 or so months to end of the trial, the share price is still languishing awaiting a new impetus from the release of new data to be released early in the 2nd half of the year.
ATH Price at posting:
0.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)